BioCryst Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 4 Sell calls were followed by roughly flat moves (-0%) three months out.
- Recent price momentum is -11.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 10.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B+
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 12.2x | Better than 67% |
| Price / Sales | 2.0x | Better than 57% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 97.8% | Better than 99% |
| Operating margin | 39.0% | Better than 95% |
| Net margin | 30.2% | Better than 90% |
| Return on equity | -1,925.4% | Better than 0% |
| Return on invested capital | -92.8% | Better than 2% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -24.4% | Better than 24% |
| 6-month return | -12.9% | Better than 35% |
| 12-month return (ex latest month) | 11.6% | Better than 48% |
| Distance below 52-week high | 35.7% | Better than 33% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.1x | Better than 57% |
| Debt to assets | 85.4% | Better than 3% |
| Interest coverage | 4.4x | Better than 54% |
| Free cash flow / net income | 130.7% | Better than 57% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 66.7% | Better than 41% |
| Upside to average target | 135.5% | Better than 89% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.32
- Open
- 7.26
- Day range
- 7.15 - 7.39
- Avg price
- 7.25
- Volume
- 3.85M
- Turnover
- 27.91M
- Turnover ratei
- 1.61%
- Volume ratioi
- 1.13
- Amplitudei
- 3.35%
- 52-week rangei
- 6.23 - 11.22
Valuation
- P/Ei
- 5.97
- P/E (TTM)i
- -5.64
- P/Bi
- -4.68
- EPSi
- 1.21
- Book value / shi
- -1.54
- Net profit
- 311.33M
- Net assets
- -397.27M
Share structure
- Market cap
- 1.86B
- Float capi
- 1.73B
- Shares out
- 257.30M
- Float sharesi
- 239.51M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
35.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-39.60M net over the window
Short interest
- Shares short
- 27.64M
- % of floati
- 10.82%
- Days to coveri
- 5.09
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of BioCryst Pharmaceuticals (BCRX)?
BioCryst Pharmaceuticals last traded at 7.22. This page shows a periodic quote snapshot. Check the displayed quote time.
What is BioCryst Pharmaceuticals's market cap?
About 1.86B.
What is the P/E ratio of BioCryst Pharmaceuticals?
The trailing twelve-month P/E is -5.64. The Valuation tab shows it against the stock's own five-year range.
Does BioCryst Pharmaceuticals pay a dividend?
BioCryst Pharmaceuticals does not currently pay a regular dividend.
Is BioCryst Pharmaceuticals a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 17.00, which implies 135.5% upside from the current price. This is not investment advice.
What is BioCryst Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates BioCryst Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
BioCryst Pharmaceuticals discussion 0 comments